Research Article

Weidong Zhou*, Peifei Li, Peihua Jin

miR-654-5p promotes gastric cancer progression via the GPRIN1/NF-κB pathway

https://doi.org/10.1515/med-2021-0369
received May 20, 2021; accepted September 6, 2021

Abstract

Background – Gastric carcinoma (GC) ranks the fifth most common cancer worldwide, with high incidence and mortality rates. Numerous microRNAs (miRNAs), including miR-654-5p, have been implicated in the pathophysiological processes of tumorigenesis. Nevertheless, the mechanism of miR-654-5p in GC is unclear.

Objectives – Our study is devoted to exploring the function and molecular mechanism of miR-654-5p on the malignant cell behaviors of GC.

Methods – The gene expression was detected by reverse transcription quantitative polymerase chain reaction. GC cell proliferation and motion were assessed by colony formation assay and transwell assay. The binding capacity between miR-654-5p and G protein-regulated inducer of neurite outgrowth 1 (GPRIN1) was explored by luciferase reporter and RNA pulldown assays. The protein levels were detected by Western blotting.

Results – miR-654-5p expression was higher in GC cells and tissues than control cells and tissues. miR-654-5p promoted GC cell growth and motion. Moreover, our findings showed that miR-654-5p was bound with GPRIN1. Importantly, downregulation of GPRIN1 rescued the inhibitory influence of miR-654-5p knockdown on GC cell malignant behaviors. Additionally, miR-654-5p activated the nuclear factor kappa-B (NF-κB) pathway by regulation of GPRIN1.

Conclusions – miR-654-5p facilitated cell proliferation, migration, and invasion in GC via targeting the GPRIN1 to activate the NF-κB pathway.

Keywords: gastric carcinoma, GPRIN1, miR-654-5p, the NF-κB pathway

1 Introduction

Gastric carcinoma (GC) is one of the most common malignant tumors worldwide due to its high incidence and mortality rates [1]. Every year about one million people are diagnosed with gastric cancer all over the world, of whom about three quarters die from this horrible disease [2]. The incidence rates of GC vary significantly between different genders and across different countries [3]. Despite greatly improved GC treatments, the prognosis is still unsatisfactory. Additionally, the overall 5-year survival rate and disease-free rate are very low in most areas of the world [4]. Thus, exploring the molecular basis of GC is essential for developing novel therapeutic treatments to improve the current poor survival rate.

MicroRNAs (miRNAs) are short noncoding RNAs, which are 22 nucleotides long and modulate gene expression in animals, plants, and protozoa [5,6]. miRNAs often bind to specific miRNAs in the 3’ untranslated region (3’ UTR) to repress protein synthesis, indicating its function after transcription [7]. Furthermore, miRNAs have been proposed to participate in not only biological processes, but also the development of numerous human diseases including cancers [8]. In almost all kinds of cancers, miRNAs are dysregulated and serve as either tumor promoters or suppressors [9,10]. Additionally, these aberrantly expressed miRNAs have significant clinical use along with diagnostic and prognostic values in human cancers [11]. Therefore, miRNAs can be recognized as biomarkers in cancers, providing novel therapeutic approaches for cancer treatment [12,13]. Increasing studies clarified that miR-654-5p is abnormally expressed in lots of cancers such as colorectal cancer, colon cancer, breast cancer, and ovarian cancer, and thus, regulates the development of cancers by targeting specific genes [14,15]. All the findings suggested that miR-654-5p may promote tumorigenesis. Previously, it has been reported that miR-654-5p downregulation influenced transmembrane protein
52B (TMEM52B, also abbreviated as C12orf59) expression in GC [16]. Nevertheless, the detailed molecular mechanism of miR-654-5p in GC requires to be elucidated.

Our previous study revealed that G protein-regulated inducer of neurite outgrowth 3 (GPRIN3) was modulated by miR-6838-5p to affect cell proliferation and motion in GC [17]. As another member of GPRIN family, G protein-regulated inducer of neurite outgrowth 1 (GPRIN1) has prognostic value and exerts biological functions in lung cancer, regulating cell epithelial–mesenchymal transition to promote lung cancer growth and metastasis, which indicates that GPRIN1 may become a useful target for lung cancer treatments [18]. Nevertheless, the function of GPRIN1 in gastric cancer is still unclear.

Nuclear factor kappa B (NF-κB) consists of a series of transcription factors which play an indispensable role during processes mediating the response to diverse external stimuli, and thus, is a pivotal element in many physiological and pathological processes [19]. The NF-κB pathway promotes the growth and survival of many solid and hematological malignancies, affecting the development of human cancers and then providing numerous targets for novel anticancer therapies [20,21]. For example, the NF-κB pathway is activated to influence nasopharynx cancer recrudescence [22]. The NF-κB pathway is blocked by Morin to suppress ovarian cancer cell proliferation, inhibit the inflammatory response, and reduce tumor size [23]. miR-10b facilitated GC cell proliferation and migration by inhibiting CUB (complement protein C1r/C1s, Uegf, and Bmp1) and Sushi multiple domains 1 expression, which caused the activating of the NF-κB pathway [24]. miR-3664-5p suppressed the growth and motion of GC cells through inhibiting the NF-κB pathway via regulating metadherin [25]. Nevertheless, whether miR-654-5p influences the NF-κB pathway via regulating GPRIN1 is unknown.

Our study was designed to reveal the effects of GPRIN1 in proliferation, migration, invasion of GC cells, and the downstream pathway of GPRIN1. The results provide great possibility for the targeted treatment of GC, driving the development of its therapeutic strategies.

2 Materials and methods

2.1 Clinical samples

Totally, 36 pairs of GC and normal tissue samples were collected from Ningbo First Hospital (Zhejiang, China). All samples were stored at −80°C for further use. This study gained approval of the Ethics Committees of Ningbo First Hospital (Zhejiang, China). Every participant had been informed of the purpose of tissue sample collection and signed an informed consent form.

2.2 Cell culture

GC cell lines (KATO III and HGC-27) and a normal gastric epithelial cell line (GES-1) were bought from Gaining Biological (Shanghai, China). The cells were incubated in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, CA, USA) containing 10% fetal bovine serum (FBS, Gibco) in a humidified atmosphere at 37°C. In some experiments, GC cells were treated with Ammonium pyrrolidinedithiocarbamate (PDTC) at the concentration of 50 μmol/L for 24 h to inhibit the NF-κB pathway [26].

2.3 Cell transfection

miR-654-5p inhibitor was employed to knockdown miR-654-5p expression with negative control (NC) inhibitor as a control. The coding sequence of GPRIN1 was cloned and inserted into the pcDNA3.1 plasmid. The above plasmids and oligonucleotides were purchased from GenePharma (Shanghai, China). Next, we used Lipofectamine 2000 (Beyotime, Shanghai, China) for transfection of the plasmids and oligonucleotides into HGC-27 and KATO III cells following the recommended instructions. Forty-eight hours later, reverse transcription quantitative polymerase chain reaction (RT-qPCR) was conducted to assess the transfection efficiency.

2.4 RT-qPCR

We used TRIzol reagent (Beyotime) to extract total RNA from GC cells and tissues following the protocols of manufactures. SuperScript Reverse Transcriptase III (Takara, Dalian, China) was used for reverse transcription of RNAs into complementary DNA (cDNA). RT-qPCR was performed with SYBR Premix Ex Taq II (Takara, Dalian, China) on an Mx3000P instrument (Strata-gene, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and RNU6 (U6) were considered as the corresponding internal controls. The 2^−ΔΔCt method was used for calculation of the fold changes. All primer sequences are available under requirement.
2.5 Cell counting kit-8 (CCK-8) assay

pcDNA3.1/GPRIN1 or empty pcDNA3.1 was transfected into HGC-27 and KATO III cells, and then cells were incubated in 96-well plates \((2 \times 10^4 \text{ cells/well})\) for 24 h, 48 h, and 72 h. Each well was added with 10 µL of CCK-8 reagent (Dojindo, Tokyo, Honshu, Japan) for another 2 h of cultivation. Finally, the microplate reader (Thermo-Fisher Scientific) was used to determine the absorbance at 450 nm.

2.6 Transwell assay

Cell migratory and invasive capabilities were evaluated by transwell assays. Transwell chamber (Corning Inc., Corning, NY) was applied to measure cell movement. In brief, cells in medium containing 1% FBS were incubated in the upper well at 37°C for 24 h. Cells failing to migrate were removed by cotton swabs and 100% methanol was utilized to fix migratory cells followed by staining with 0.5% crystal violet. The inverted microscope (Olympus Corporation, Tokyo, Japan) was utilized to image the cells. Cell invasive ability was detected by Transwell invasion assay, which is like the migration assay except that the chambers contained 1 mg/mL matrigel (Coming Inc.). Number of migratory and invaded cells was counted to measure cell migratory and invasive abilities, respectively.

2.7 Colony formation assay

Transfected GC cells were diluted and seeded onto 6-well plates \((1,000 \text{ cells/well})\). HGC-27 and KATO III cells were cultured for 14 days with 5% CO\(_2\) and 95% air at 37°C. After fixation and staining, the colony numbers were observed and counted under a microscope.

2.8 RNA pulldown assay

RNA pulldown assay was conducted to examine the binding of GPRIN1 and miR-654-5p. After lysing, GC cells were treated with RNase-free DNase I (Beyotime). Afterwards, the biotin-labeled wild-type miR-654-5p (bio-miR-654-5p WT), biotin-labeled mutant miR-654-5p (bio-miR-654-5p MUT) or bio-NC, and streptavidin-coated magnetic beads (Sigma-Aldrich, St Louis, MO, USA) were incubated with cell lysate at 4°C for 3 h. Finally, RNA samples were isolated by TRIzol and subjected to RT-qPCR analysis.

2.9 Dual luciferase reporter assay

The 3’ UTR of GPRIN1 was amplified from the full-length cDNA by PCR. After digestion with XhoI and NotI, the 3’-UTR fragment was cloned into the XhoI/NotI sites of the psiCHECK-2 vector (Promega) to obtain a wild-type (Wt) GPRIN1 3’-UTR-luciferase reporter plasmid. A mutant (Mut) GPRIN1 3’-UTR-luciferase reporter plasmid was constructed using a QuickMutation™ Site-Directed Mutagenesis Kit (Beyotime). Luciferase reporter assay was performed by cotransfection with 250 ng of luciferase reporter vectors and miR-654-5p inhibitor or NC inhibitor (10 nM) using Lipofectamine 2000 (Invitrogen). After 48 h, the GC cells were assayed for luciferase activities on a Dual Luciferase Reporter Assay System (Promega). The firefly luciferase activity values were normalized to Renilla luciferase values to exclude the effects of difference in transfection efficiency.

2.10 Western blotting

The protein contents in GC cells and tissues were isolated by radio-immunoprecipitation assay lysis buffer containing phenylmethylsulfonyl fluoride. The concentration of protein was determined using a bicinchoninic acid kit (Beyotime). Afterwards, the proteins were transferred onto a polyvinylidene fluoride membrane (Millipore, USA) after being separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After being blocked with 5% nonfat milk powder, the membranes were cultured with primary antibodies at 4°C overnight, followed by cultivation with secondary antibodies (TransGen Biotech, Beijing, China) for 1 h. The signals of protein bands were observed, and the images were analyzed using ImageJ software (National Institutes of Health, MD, USA).

2.11 NF-κB activity assay

KATO III and HGC-27 cells were cultured for 24 h in 6-well plates \((5 \times 10^4 \text{ cells/well})\). Next, GC cells were transfected with the NF-κB reporter luciferase construct. After 6 h, cells were washed and co-transfected with miR-654-5p inhibitor and sh-GPRIN1 for another 24 h. Afterwards, transfected cells were washed in PBS and harvested in lysis buffer. A Promega luciferase assay kit was then used to examine luciferase activity. Finally, the experimental values were recorded in comparison with the positive and negative control samples.
2.12 Animal studies

Twenty-four-week-old female BALB/c nude mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd (Beijing, China) and raised in the specific pathogen-free animal room. All mice experiments were performed according to the guideline of the Ethics Committee of the Institutional Animal Care and Use Subcommittee of the Ningbo First Hospital (Zhejiang, China). Mice were randomly divided into four groups: (i) NC inhibitor (n = 5), (ii) miR-654-5p inhibitor (n = 5), (iii) miR-654-5p inhibitor + sh-GPRIN1 (n = 5), and (iv) miR-654-5p inhibitor + sh-GPRIN1 + PDTC (n = 5). 2 × 10^6 HGC-27 cells stably transfected by lentivirus conveying NC inhibitor, miR-654-5p inhibitor, or sh-GPRIN1 were injected into the left subcutaneous armpit areas of mice to develop a tumor-bearing mouse model. After tumor inoculation for 7 days, PDTC (50 mg/kg/day) was intra-peritoneally daily injected into mice in the miR-654-5p inhibitor + sh-GPRIN1 + PDTC group. The tumor volume was calculated \( V = 0.5 \times A \times B^2 \), \( V \) refers to volume, \( A \) refers to longest diameter, \( B \) refers to the shortest diameter) every 3 days. On day 21, mice were euthanized, and the tumors were collected for weighing.

2.13 Statistical analysis

The SPSS 20.0 software was employed to analyze relative statistical data. The comparison between different groups was analyzed by the Student’s t-test or one-way ANOVA. Pearson’s correlation analysis was conducted to evaluate gene expression correlation. \( p \) values less than 0.05 were significant.

3 Results

3.1 GPRIN1 is downregulated in GC cells and tissues

Although GPRIN1 was proved to be a vital regulator in numerous human cancers, its role in GC remains unclear yet. To clarify this, we first compared GPRIN1 expression between GC and NC. RT-qPCR showed that GPRIN1 expression was lower in GC tissues than in non-tumor tissues (Figure 1a). According to starBase website (http://starbase.sysu.edu.cn/), low expression level of GPRIN1 is closely associated with the low survival rates of GC patients (Figure 1b). Furthermore, GPRIN1 expression was decreased at the miRNA and protein levels in GC cells (HGC-27 and KATO III) compared to normal gastric epithelial cell line GES-1 (Figure 1c and d). In conclusion, GPRIN1 expresses at a low level in GC.

3.2 GPRIN1 inhibits growth and motion of GC cells

To explore the underlying function of GPRIN1 in GC, GPRIN1 was overexpressed in HGC-27 and KATO III cells to examine potential gain-of-functions. The RT-qPCR results revealed that the GPRIN1 overexpression vector significantly elevated GPRIN1 expression in HGC-27 and KATO III cells (Figure 2a). Next, we detected the regulatory effects of GPRIN1 on GC cell proliferation and motion. CCK-8 assay showed that GPRIN1 overexpression suppressed GC cell viability compared with the NC group (Figure 2b). Colony formation assay demonstrated that GC cell proliferation was inhibited by GPRIN1 (Figure 2c). The results of Transwell assays demonstrated that GPRIN1 attenuated the migratory and invasive ability of GC cells (Figure 2d and e). Collectively, GPRIN1 inhibited GC cell proliferation, migration, and invasion.

3.3 miR-654-5p targets GPRIN1 in GC cells

miRNAs were confirmed to relate to GC progression [27–29]. Increasing evidence suggested that miR-654-5p had regulatory influence on numerous human cancers [14,15]. To explore the role of miR-654-5p in GC, we first detected miR-654-5p level in GC cells. RT-qPCR indicated that miR-654-5p expression level was increased in GC tissues (Figure 3a). StarBase website also showed that miR-654-5p level was higher in GC samples compared to normal samples (Figure 3b). High expression of miR-654-5p is closely associated with poor overall survival of GC patients according to Kaplan-Meier Plotter website (https://kmplot.com/) (Figure 3c). Furthermore, a negative expression correlation between miR-654-5p and GPRIN1 was observed in 36 collected GC tissues (Figure 3d). miR-654-5p was also overexpressed in GC cells compared to that in normal cells (Figure 3e). To figure out the exact role of miR-654-5p in GC, a series of loss-of-function experiments were taken by transfecting miR-654-5p inhibitor or NC inhibitor into GC cells. RT-qPCR showed that miR-654-5p inhibitor decreased miR-654-5p expression in HGC-27 and KATO III cells (Figure 3f). Importantly, both GPRIN1 mRNA
expression and protein level were significantly increased by miR-654-5p inhibition (Figure 3g). Additionally, an RNA pulldown assay revealed that GPRIN1 was highly enriched in bio-miR-654-5p WT in comparison with bio-NC (Figure 3h), suggesting that GPRIN1 was bound to the wild-type miR-654-5p. GPRIN1 was not significantly pulled down by bio-miR-654-5p MUT. Results of the luciferase reporter assay revealed that luciferase activity of psiCHECK-2-GPRIN1 3′ UTR WT was higher in HGC-27 and KATO III cells transfected with miR-654-5p inhibitor than those transfected with NC inhibitor. There was no significant difference between luciferase activity of psiCHECK-2-GPRIN1 3′ UTR Mut under transfections of miR-654-5p inhibitor and NC inhibitor (Figure 3i). Figure 3la revealed that GPRIN3 expression was not impacted by miR-654-5p inhibitor, miR-654-5p inhibitor had more stimulating effects on GPRIN1 expression than on C12orf59 expression in GC cells.

3.4 miR-654-5p downregulation inhibits proliferation, migration, and invasion of GC cells by GPRIN1

A series of rescue experiments were performed to verify whether GPRIN1 contributes to the miR-654-5p-induced tumor promotion in GC. We transfected sh-GPRIN1 into miR-654-5p-silenced HGC-27 and KATO III cells. The findings indicated that miR-654-5p downregulation inhibited GC cell proliferation and motion, while transfection of sh-GPRIN1 rescued the inhibitory effects of miR-654-5p inhibitor on GC cells (Figure 4a–d). Figure S1b revealed that the rescue effect of sh-GPRIN1 on miR-654-5p inhibitor in GC cell viability was more significant than that of sh-C12orf59, indicating that GPRIN1 plays a more important role than C12orf59 in miR-654-5p-mediated GC cells.
Figure 2: GPRIN1 inhibits proliferation, migration, and invasion of GC cells. (a) HGC-27 and KATO III cells were transfected with pcDNA3.1/GPRIN1, and the overexpression efficiency was examined by RT-qPCR. (b) GC cell viability after GPRIN1 overexpression was detected by a CCK-8 assay. (c) Influences of GPRIN1 on GC cell proliferation were explored by a colony formation assay. (d and e) Transwell assays were performed to reveal the migration and invasion of GC cells transfected with pcDNA3.1/GPRIN1. **p < 0.01, ***p < 0.001.
Figure 3: miR-654-5p targets GPRIN1 in GC cells. (a) Relative miR-654-5p level in 36 GC tissues compared to that in 36 normal tissues was assessed by RT-qPCR. (b) miR-654-5p expression pattern in 372 GC samples and 32 normal samples was analyzed according to starBase website (http://starbase.sysu.edu.cn/). (c) High level of miR-654-5p was related to poor overall survival of GC patients according to Kaplan-Meier Plotter website. (d) The correlation between miR-654-5p and GPRIN1 expression levels in GC tissues was analyzed by Spearman’s correlation analysis. (e) Relative miR-654-5p level in GC cells compared to that in GES-1 cells was measured by RT-qPCR. (f) HGC-27 and KATO III cells were transfected with miR-654-5p inhibitor, and RT-qPCR assessed the transfection efficiency. (g) RT-qPCR and Western blotting were conducted to reveal relative mRNA and protein levels of GPRIN1 in GC cells transfected with miR-654-5p inhibitor compared to GC cells transfected with NC inhibitor. (h) An RNA pulldown assay showed the relative enrichment of GPRIN1 in bio-miR-654-5p WT and bio-miR-654-5p MUT compared to that in bio-NC. (i) A luciferase reporter assay was conducted to reveal the binding of miR-654-5p and GPRIN1 3’UTR. **p < 0.01, ***p < 0.001.
Figure 4: miR-654-5p knockdown inhibits proliferation, migration, and invasion of GC cells by GPRIN1. (a–d) CCK-8, colony formation, and Transwell assays revealed that GPRIN1 knockdown rescued the inhibition in the proliferation, migration, and invasion of HGC-27 and KATO III cells caused by miR-654-5p inhibitor. **p < 0.01, ***p < 0.001.
Figure 5: miR-654-5p modulates the NF-kB pathway by GPRIN1. (a) NF-kB transcriptional activity was measured in HGC-27 and KATO III cells after GPRIN1 overexpression. (b) HGC-27 and KATO III cells were transfected with pcDNA3.1/GPRIN1 and empty pcDNA3.1. Protein levels of NF-kB p65, p-NF-kB p65, IκBα, and p-NF-kB IκBα in HGC-27 and KATO III cells were examined by Western blotting. (c) NF-kB transcriptional activity in HGC-27 and KATO III cells co-transfected with miR-654-5p inhibitor and sh-GPRIN1 was measured. (d) GC cells were co-transfected with miR-654-5p inhibitor and sh-GPRIN1 and corresponding controls. Protein levels of NF-kB p65, p-NF-kB p65, IκBα, and p-NF-kB IκBα were detected by Western blotting. (e) Influence of PDTC on relative expression of miR-654-5p was detected by RT-qPCR. (f) Relative expression of GPRIN1 in the control, PDTC, miR-654-5p inhibitor, miR-654-5p inhibitor + PDTC, miR-654-5p inhibitor + sh-GPRIN1, and miR-654-5p inhibitor + sh-GPRIN1 + PDTC groups was detected by RT-qPCR. *p < 0.05, **p < 0.01.
3.5 miR-654-5p regulates the NF-κB pathway by GPRIN1

The NF-κB pathway was proposed many times to participate in GC tumorigenesis [30–33]. We inferred that miR-654-5p regulates the NF-κB pathway by GPRIN1. To examine the connection between GPRIN1 and the NF-κB pathway, pcDNA3.1/GPRIN1 and the corresponding control were transfected into GC cells. NF-κB activity assay showed that NF-κB transcriptional activity was suppressed by GPRIN1 overexpression compared with the NC group (Figure 5a). Furthermore, Western blotting indicated that GPRIN1 overexpression significantly decreased the protein levels of p-NF-κB p65 and p-NF-κB IkBα. Basal protein levels of NF-κB p65 and NF-κB IkBα are not significantly influenced (Figure 5b). We found that silencing of miR-654-5p suppressed the NF-κB pathway, while GPRIN1 knockdown rescued the inhibitory influence of miR-654-5p inhibitor on NF-κB transcriptional activity (Figure 5c). The decreased protein levels of p-NF-κB p65 and p-NF-κB IkBα caused by miR-654-5p downregulation were reversed by GPRIN1 knockdown (Figure 5d). In summary, miR-654-5p activated the NF-κB pathway by regulation of GPRIN1. Moreover, we detected the influence of PDTC, an inhibitor of the NF-κB pathway, on the miR-654-5p/GPRIN1 axis. Figure 5e revealed that PDTC had no significant effects on miR-654-5p expression. Figure 5f revealed that PDTC influenced neither GPRIN1 expression nor the effect of silenced miR-654-5p on GPRIN1 expression.
3.6 Role of the miR-654-5p/GPRIN1/NF-κB pathway in a tumor-bearing mouse model

miR-654-5p expression was lower, while GPRIN1 expression was higher, in tumors of the miR-654-5p inhibitor group than NC inhibitor group. PDTC had no significant effects on miR-654-5p or GPRIN1 expression (Figure 6a). Mice with miR-654-5p deficiency exhibited smaller tumor size and reduced tumor volume and weight than control mice. Mice in the miR-654-5p inhibitor + sh-GPRIN1 group showed increased tumor size, volume, and weight than mice in the miR-654-5p inhibitor group. Moreover, reduced tumor size, volume, and weight were observed in mice with NF-κB inhibition by PDTC administration (Figure 6b–d). All these findings implied that silenced miR-654-5p suppressed GC tumor growth in mice by the GPRIN1/NF-κB pathway.

4 Discussion

As one of the leading cancers worldwide, GC is a great threat to human health due to its high morbidity and mortality [34]. It is crucial to clarify the underlying molecular mechanisms of GC to diagnose tumors and develop effective therapeutic strategies [35]. Although increasing studies reported that many miRNAs participated in biological processes associated with GC progression, including cell proliferation, differentiation, apoptosis, and invasion [36–39], further investigations are required to ascertain the underlying mechanisms of the miRNA-induced network in GC. Furthermore, accumulating evidence demonstrated that miR-654-5p is a significant regulator involved in numerous cancers. For instance, miR-654-5p is upregulated to regulate colorectal cancer progression through targeting hematopoietic cell-specific Lyn substrate 1-associated protein X-1 [14]. miR-654-5p targets growth factor receptor-bound protein 2-related adaptor protein to drive oral squamous cell carcinoma cell growth and migration [40]. miR-654-5p suppresses ovarian cancer tumorigenesis by targeting CUB domain containing protein 1 and pleiomorphic adenoma gene 1 like zinc finger 2 [41]. Nevertheless, the specific role and detailed mechanism of miR-654-5p in GC require further investigation. Our work was designed to explore the biological function, as well as the molecular mechanisms of miR-654-5p in GC. Bioinformatic analysis showed elevated expression of miR-654-5p in GC cells and tissues. Additionally, miR-654-5p downregulation suppressed the growth and motion of GC cells. Finally, high expression of miR-654-5p is associated with the poor overall survival of GC patients. Overall, these findings illustrated that miR-654-5p promoted the progression of GC.

Previously, GPRIN3, a member of GPRIN family, has been indicated to be modulated by miR-6838-5p to affect cell growth and migration in GC [17]. Herein, we explored the role of another member of GPRIN family, GPRIN1, in the development of GC. Our study found that GPRIN1 expression was downregulated in GC cells and tissues. Furthermore, GPRIN1 inhibited the malignant behaviors of GC cells. GPRIN1 was also confirmed to be a miR-654-5p target. Additionally, GPRIN1 was found to be negatively modulated by miR-654-5p in GC. Rescue assays indicated that miR-654-5p facilitated the development of GC via modulating GPRIN1.

The NF-κB pathway has been widely acknowledged as a significant regulator during biological processes in gastric cancer [42–44]. In our current study, miR-654-5p downregulation blocked the NF-κB signaling pathway, while the inhibitory effects were reversed by GPRIN1 knockdown. It could be inferred that the NF-κB pathway was involved in the miR-654-5p-mediated regulation of GC. Importantly, the miR-654-5p/GPRIN1 axis was not impacted by the NF-κB pathway.

In conclusion, our study revealed that miR-654-5p promoted cell proliferation, migration, and invasion of GC via targeting GPRIN1 and activating the NF-κB pathway, which provided novel sights for GC treatment.

Funding information: No funding.

Author contributions: W.Z. and P.J. designed the study, analyzed the data. P.L. wrote the manuscript. All authors read and approved the final manuscript.

Conflict of interest: The authors declare that there are no competing interests in this study.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.

[2] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
[3] Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20(4):633–49.

[4] Cunningham SC, Kamangaar F, Kim MP, Hammad S, Haque R, Malitra A, et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg. 2005;9(5):718–25.

[5] Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer—a brief overview. Adv Biol Regul. 2015;57:1–9.

[6] Fu X, Dong D. Bioinformatic analysis of microRNA sequencing data. Methods Mol Biol (Clifton, NJ). 2018;1751:109–25.

[7] Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.

[8] Vishnoi A, Rani S. miRNA biogenesis and regulation of disease: an overview. Methods Mol Biol (Clifton, NJ). 2017;1509:1–10.

[9] Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369–84.

[10] Van Roosbroeck K, Calin GA. Cancer hallmarks and microRNAs: the therapeutic connection. Adv Cancer Res. 2017;135:119–49.

[11] Wu Q, Yang Z, Shi Y, Fan D. miRNAs in human cancers: the diagnostic and therapeutic implications. Curr Pharm Des. 2014;20(33):5336–47.

[12] Cortez MA, Anfossi S, Ramapriyan R, Menon H, Atalar SC, Aliru M, et al. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58(4):244–53.

[13] Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC, et al. miRNA nanotherapeutics for cancer. Drug Discov Today. 2017;22(2):424–32.

[14] Huang F, Wu X, Wei M, Guo H, Li H, Shao Z, et al. miR-654-5p targets HAX-1 to regulate the malignancy behaviors of colorectal cancer cells. BioMed Res Int. 2020;2020:4914707.

[15] Li P, Cai JX, Han F, Wang J, Zhou JJ, Shen KW, et al. Expression and significance of miR-654-5p and miR-376b-3p in patients with colon cancer. World J Gastrointest Oncol. 2020;12(4):492–502.

[16] Zhang JX, He WL, Feng ZH, Chen DL, Gao Y, He Y, et al. A positive feedback loop consisting of C12orf59/NF-xB/CDH11 promotes gastric cancer invasion and metastasis. J Exp Clin Cancer Res. 2019;38(1):164.

[17] Zhou W, Ding X, Jin P, Li P. miR-683B-5p affects cell growth, migration, and invasion by targeting GPRIN3 via the Wnt/β-Catenin signaling pathway in gastric cancer. Pathobiology. 2020;87(6):327–37.

[18] Zhuang MQ, Li J, Han X, Su KL, Hao GJ, Han JQ. G protein regulated inducer of neurite outgrowth 1 is a potential marker for lung cancer prognosis. J Biol Regul Homeost Agents. 2020;34(3):853–64.

[19] Oechkingshaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034.

[20] Hoesel B, Schmid JA. The complexity of NF-xB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.

[21] Mitchell S, Vargas J, Hoffmann A. Signaling via the Nf-κB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227–41.

[22] You R, Liu YP, Lin DC, Li Q, Yu T, Zou X, et al. Clonal mutations activate the NF-xB pathway to promote recurrence of nasopharyngeal carcinoma. Cancer Res. 2019;79(23):5930–43.

[23] Xu M, Zhang Y. Morin inhibits ovarian cancer growth through the inhibition of NF-xB signaling pathway. Anti-Cancer Agents Med Chem. 2019;19(18):2243–50.

[24] Chen XL, Hong LL, Wang KL, Liu X, Wang JL, Lei L, et al. Deregulation of CSMD1 targeted by microRNA-10b drives gastric cancer progression through the NF-xB pathway. Int J Biol Sci. 2019;15(10):2075–86.

[25] Jiao Y, Yang H, Qian J, Gong Y, Liu H, Wu S, et al. miR-3664-S5 suppresses the proliferation and metastasis of gastric cancer by attenuating the NF-xB signaling pathway through targeting MTDH. Int J Oncol. 2019;54(3):845–58.

[26] Zhang HM, Sang XG, Wang YZ, Cui C, Zhang L, Ji WS. Role of Δ33p53 isoform in NF-xB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells. World J Gastroenterol. 2017;23(15):2716–22.

[27] Safari N, Abediankari S. MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell. Tumour Biol. 2019;40(5):1010428317701652.

[28] Li Z, Liu ZM, Xu BH. A meta-analysis of the effect of microRNA-34a on the progression and prognosis of gastric cancer. Eur Rev Med Pharmacol Sci. 2018;22(23):8281–9.

[29] Shin VY, Chu KM. miRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 2016;20(30):10432–9.

[30] Fan H, Zhang S, Zhang Y, Liang W, Cao B. FERMT1 promotes gastric cancer progression by activating the NF-xB pathway and predicts poor prognosis. Cancer Biol Ther. 2020;21(9):815–25.

[31] Liu C, He X, Liu X, Yu J, Zhang M, Yu F, et al. RPS15A promotes gastric cancer progression via activation of theAkt/IKK-β/NF-xB signalling pathway. J Cell Mol Med. 2019;23(3):2207–18.

[32] Ni SJ, Zhao LQ, Wang XF, Wu ZH, Hua RX, Wan CH, et al. CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-xB-miR-21 pathways. J Hematol Oncol. 2018;11(1):17.

[33] Shen Y, Xue C, Li X, Ba L, Gu J, Sun Z, et al. Effects of gastric cancer cell-derived exosomes on the immune regulation of mesenchymal stem cells by the NF-xB signaling pathway. Stem Cell Dev. 2019;28(7):464–76.

[34] Petryszyn P, Chapelle N, Matysiak-Budnik T. Gastric cancer: where are we heading? Digestive Dis (Basel, Switz). 2020;38(4):280–5.

[35] Hudler P. Outlook on epigenetic therapeutic approaches for treatment of gastric cancer. Curr Cancer Drug Targets. 2018;18(1):65–88.

[36] Deng S, Zhang X, Qin Y, Chen W, Fan H, Feng X, et al. miRNA-192 and -215 activate Wnt/β-catenin signaling pathway in gastric cancer via APC. J Cell Physiol. 2020;203(9):6218–29.

[37] Meng H, Li YY, Han D, Zhang CY. miRNA-93-5p promotes the biological progression of gastric cancer cells via Hippo signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(11):4763–9.

[38] Peng Y, Zhang X, Ma Q, Yan R, Qin Y, Zhao Y, et al. miRNA-194 activates the Wnt/β-catenin signaling pathway in gastric
cancer by targeting the negative Wnt regulator, SUFU. Cancer Lett. 2017;385:117–27.

[39] Wang C, Huang Y, Zhang J, Fang Y. miRNA-339-5p suppresses the malignant development of gastric cancer via targeting ALKBH1. Exp Mol Pathol. 2020;115:104449.

[40] Lu M, Wang C, Chen W, Mao C, Wang J. miR-654-5p targets GRAP to promote proliferation, metastasis, and chemoresistance of oral squamous cell carcinoma through Ras/MAPK signaling. DNA Cell Biol. 2018;37(4):381–8.

[41] Majem B, Parrilla A, Jiménez C, Suárez-Cabrera L, Barber M, Marín A, et al. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene. 2019;38(32):6035–50.

[42] Fu Z, Lin L, Liu S, Qin M, He S, Zhu L, et al. Ginkgo biloba extract inhibits metastasis and ERK/nuclear factor kappa B (NF-κB) signaling pathway in gastric cancer. Med Sci Monit. 2019;25:6836–45.

[43] Kong FB, Deng QM, Deng HQ, Dong CC, Li L, He CG, et al. Siva-1 regulates multidrug resistance of gastric cancer by targeting MDR1 and MRP1 via the NF-κB pathway. Mol Med Rep. 2020;22(2):1558–66.

[44] Zang YQ, Feng YY, Luo YH, Zhai YQ, Ju XY, Feng YC, et al. Glycitein induces reactive oxygen species-dependent apoptosis and G0/G1 cell cycle arrest through the MAPK/STAT3/NF-κB pathway in human gastric cancer cells. Drug Dev Res. 2019;80(5):573–84.